还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

7 B9 v" |% [' Q8 Q4 b9 e% k5 h  y请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  

6 O; ]* ?$ ^1 [5 a% h" x
Sub-category:
Molecular Targets
; s* [9 e3 T" i$ N8 s

Category:
+ w$ h' H+ p$ V+ {2 q: NTumor Biology


! Q/ Q- M" m1 H# fMeeting:
" `' Z4 Z% d+ m3 x# z8 j. C2011 ASCO Annual Meeting
1 m% z) f; S+ s' {+ |8 C7 a
! ^, }5 _  P- g" L, p; M
Session Type and Session Title:
4 U; e& w* C4 Z3 b2 iPoster Discussion Session, Tumor Biology


: a8 d4 v1 L% C$ FAbstract No:
10517

. m. m; S% ~  L( M8 |. h: k3 A! U
Citation:
7 O, M! p  q9 _J Clin Oncol 29: 2011 (suppl; abstr 10517)
7 C! K" f5 [. [
* }# A# e! i0 C$ j
* O9 k# H- C) f) Z0 G8 OAuthor(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
: s: B5 g. ]* ?) I" X1 d5 G/ X

  T* |$ T4 F- l# l0 h
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# `8 m/ j4 R" _& E
( [9 b: f1 O; L( e0 J: M) rAbstract Disclosures
7 q, J" ]8 p  ?9 y% Y& g, e& K
. i1 s) M) W$ q' hAbstract:

0 O& Q2 O) ]2 W# t; _. I: Q/ {
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
, k  I. [. X; q) y7 h9 K

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

& u1 g1 x3 S5 q没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

# C' k7 @9 Y; W化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

( G) G- X3 J  i  n4 S" n* H: |6 W                               
登录/注册后可看大图

1 d& a1 D* u0 B: m易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
( F( u( h. l( ~. i  sALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
" s8 M/ Q; B+ j/ I
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊